These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29667115)

  • 1. Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints.
    Rauch GM; Kuerer HM; Adrada B; Santiago L; Moseley T; Candelaria RP; Arribas E; Sun J; Leung JWT; Krishnamurthy S; Yang WT
    Ann Surg Oncol; 2018 Jul; 25(7):1953-1960. PubMed ID: 29667115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
    Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
    Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy: A Nonrandomized Controlled Trial.
    Sutton EJ; Braunstein LZ; El-Tamer MB; Brogi E; Hughes M; Bryce Y; Gluskin JS; Powell S; Woosley A; Tadros A; Sevilimedu V; Martinez DF; Toni L; Smelianskaia O; Nyman CG; Razavi P; Norton L; Fung MM; Sedorovich JD; Sacchini V; Morris EA
    JAMA Netw Open; 2021 Jan; 4(1):e2034045. PubMed ID: 33449096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
    Kuerer HM; Rauch GM; Krishnamurthy S; Adrada BE; Caudle AS; DeSnyder SM; Black DM; Santiago L; Hobbs BP; Lucci A; Gilcrease M; Hwang RF; Candelaria RP; Chavez-MacGregor M; Smith BD; Arribas E; Moseley T; Teshome M; Miggins MV; Valero V; Hunt KK; Yang WT
    Ann Surg; 2018 May; 267(5):946-951. PubMed ID: 28549010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.
    Tasoulis MK; Lee HB; Yang W; Pope R; Krishnamurthy S; Kim SY; Cho N; Teoh V; Rauch GM; Smith BD; Valero V; Mohammed K; Han W; MacNeill F; Kuerer HM
    JAMA Surg; 2020 Dec; 155(12):e204103. PubMed ID: 33026457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
    Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
    Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.
    Lee SC; Grant E; Sheth P; Garcia AA; Desai B; Ji L; Groshen S; Hwang D; Yamashita M; Hovanessian-Larsen L
    J Ultrasound Med; 2017 May; 36(5):901-911. PubMed ID: 28150325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy.
    Narui K; Ishikawa T; Oba MS; Hasegawa Y; Kaise H; Kawate T; Yamada A; Yamada K; Suzuki Y; Niikura N; Kohno N; Kimoto T; Sugae S; Kosaka Y; Miyashita M; Okamura T; Shimizu D; Tanino H; Tanabe M; Morita S; Endo I; Tokuda Y
    Surg Oncol; 2020 Dec; 35():447-452. PubMed ID: 33045629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective trial of breast MRI versus 2D and 3D ultrasound for evaluation of response to neoadjuvant chemotherapy.
    Lee MC; Gonzalez SJ; Lin H; Zhao X; Kiluk JV; Laronga C; Mooney B
    Ann Surg Oncol; 2015 Sep; 22(9):2888-94. PubMed ID: 25589151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of digital mammography, ultrasound and MRI in predicting the pathological complete response and residual tumor size of breast cancer after completion of neoadjuvant chemotherapy.
    Sudhir R; Koppula VC; Rao TS; Sannapareddy K; Rajappa SJ; Murthy SS
    Indian J Cancer; 2022; 59(3):345-353. PubMed ID: 33753611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).
    van der Noordaa MEM; van Duijnhoven FH; Loo CE; van Werkhoven E; van de Vijver KK; Wiersma T; Winter-Warnars HAO; Sonke GS; Vrancken Peeters MTFD
    Breast; 2018 Aug; 40():76-81. PubMed ID: 29698928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy.
    Um E; Kang JW; Lee S; Kim HJ; Yoon TI; Sohn G; Chung IY; Kim J; Lee JW; Son BH; Ahn SH; Ko BS
    Clin Breast Cancer; 2018 Oct; 18(5):e1087-e1091. PubMed ID: 29703689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
    Heil J; Schaefgen B; Sinn P; Richter H; Harcos A; Gomez C; Stieber A; Hennigs A; Rauch G; Schuetz F; Sohn C; Schneeweiss A; Golatta M
    Eur J Cancer; 2016 Dec; 69():142-150. PubMed ID: 27821317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining radiologic complete response using a correlation of presurgical ultrasound and mammographic localization findings with pathological complete response following neoadjuvant chemotherapy in breast cancer.
    Makanjuola DI; Alkushi A; Al Anazi K
    Eur J Radiol; 2020 Sep; 130():109146. PubMed ID: 32673929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
    Heil J; Sinn P; Richter H; Pfob A; Schaefgen B; Hennigs A; Riedel F; Thomas B; Thill M; Hahn M; Blohmer JU; Kuemmel S; Karsten MM; Reinisch M; Hackmann J; Reimer T; Rauch G; Golatta M
    BMC Cancer; 2018 Aug; 18(1):851. PubMed ID: 30144818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sentinel lymph node biopsy by ultrasound-guided core needle biopsy for patients with suspicious node positive breast cancer.
    Nakamura R; Yamamoto N; Miyaki T; Itami M; Shina N; Ohtsuka M
    Breast Cancer; 2018 Jan; 25(1):86-93. PubMed ID: 28735457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model combining BI-RADS® descriptors from pre-treatment B-mode breast ultrasound with clinicopathological tumor features shows promise in the prediction of residual disease after neoadjuvant chemotherapy.
    Kapetas P; Aggarwal R; Altuwayjiri B; Pinker K; Clauser P; Helbich TH; Baltzer PAT
    Eur J Radiol; 2024 Sep; 178():111649. PubMed ID: 39094464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcifications on mammogram do not correlate with tumor size after neoadjuvant chemotherapy.
    Weiss A; Lee KC; Romero Y; Ward E; Kim Y; Ojeda-Fournier H; Einck J; Blair SL
    Ann Surg Oncol; 2014 Oct; 21(10):3310-6. PubMed ID: 25056851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
    Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
    JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint.
    Johnson HM; Valero V; Yang WT; Smith BD; Krishnamurthy S; Shen Y; Lin H; Lucci A; Rauch GM; Kuerer HM
    J Am Coll Surg; 2023 Jul; 237(1):101-108. PubMed ID: 36856291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.